News
Watch
Conferences
Publications
Events
CE
Resources
Subscribe

Spotlight -

Community/Retail|

Health Systems|

Pharmacy Technician|

Opinion|Videos|April 1, 2024

Key Takeaways Regarding Operationalizing Bispecific Antibodies for MM

Panelists summarize key takeaways on using bispecific antibodies for multiple myeloma treatment.

Episodes in this series

Video 1 - "Impact of Bispecific Antibodies on Multiple Myeloma Treatment"

EP. 1 Impact of Bispecific Antibodies on Multiple Myeloma Treatment

Video 2 - "Key Considerations in Treatment Selection for Patients With Multiple Myeloma"

EP. 2 Key Considerations in Treatment Selection for Patients With Multiple Myeloma

Video 3 - "Monitoring and Treating Adverse Events in Patients Receiving Treatment With a Bispecific Antibody"

EP. 3 Monitoring and Treating Adverse Events in Patients Receiving Treatment With a Bispecific Antibody

Video 4 - "Risk Evaluation Mitigation Strategy (REMS) Program Requirements for Bispecific Antibodies"

EP. 4 Risk Evaluation Mitigation Strategy (REMS) Program Requirements for Bispecific Antibodies

Video 5 - "The Importance of Engaging Stakeholders When Implementing Bispecific Antibodies"

EP. 5 The Importance of Engaging Stakeholders When Implementing Bispecific Antibodies

Video 6 - "Stakeholder Perspective: Step-Up Dosing for Bispecific Antibodies in Multiple Myeloma"

EP. 6 Stakeholder Perspective: Step-Up Dosing for Bispecific Antibodies in Multiple Myeloma

Video 7 - "Overcoming Challenges Related to Bispecific Antibody Adoption in Multiple Myeloma"

EP. 7 Overcoming Challenges Related to Bispecific Antibody Adoption in Multiple Myeloma

Video 8 - "Final Thoughts on Operationalization of Bispecific Antibodies for Multiple Myeloma"

EP. 8 Final Thoughts on Operationalization of Bispecific Antibodies for Multiple Myeloma

Video 09 - "Step-Up Dosing of Bispecifics in the Outpatient Setting for Patients with Multiple Myeloma"

EP. 9 Step-Up Dosing of Bispecifics in the Outpatient Setting for Patients with Multiple Myeloma

Video 09 - "Step-Up Dosing of Bispecifics in the Outpatient Setting for Patients with Multiple Myeloma"

EP. 10 Multidisciplinary Team Approach to Adverse Effect Monitoring for Bispecifics in MM

Video 11 - "Complying with REMS Training and Documentation Requirements"

EP. 11 Complying with REMS Training and Documentation Requirements

Video 12 - "Pharmacist Role in Addressing Operational Challenges of Bispecifics in MM"

EP. 12 Pharmacist Role in Addressing Operational Challenges of Bispecifics in MM

Video 12 - "Pharmacist Role in Addressing Operational Challenges of Bispecifics in MM"

EP. 13 Unmet Needs in Multiple Myeloma Care

Video 12 - "Pharmacist Role in Addressing Operational Challenges of Bispecifics in MM"

EP. 14 Treatment Sequencing and Combination Therapies for MM

Video 15 - "Key Takeaways Regarding Operationalizing Bispecific Antibodies for MM "

EP. 15 Key Takeaways Regarding Operationalizing Bispecific Antibodies for MM

Video 1 - "Impact of the Introduction of Bispecifics on the Management of Multiple Myeloma"

EP. 16 Impact of the Introduction of Bispecifics on the Management of Multiple Myeloma

Video 2 - "Key Results From the MajesTEC-1, MonumenTAL-1, and MagnetisMM-3 Trials"

EP. 17 Key Results From the MajesTEC-1, MonumenTAL-1, and MagnetisMM-3 Trials

A panel of 3 experts on multiple myeloma

EP. 18 Identifying Patients Who Are Candidates for Bispecifics and Referring Patients for Care

A panel of 3 experts on multiple myeloma

EP. 19 Collaborating with Other Care Providers to Optimize Outcomes for Patients Receiving Bispecifics

A panel of 3 experts on multiple myeloma

EP. 20 Considerations for Maintenance Therapy in the Community Oncology Setting

A panel of 3 experts on multiple myeloma

EP. 21 Team Approach to Meeting REMS Program Requirements

Video 7 - "Role of Pharmacists in Operationalizing Bispecific Antibodies"

EP. 22 Role of Pharmacists in Operationalizing Bispecific Antibodies

Video 8 - "Bispecific Antibodies Versus CAR T-Cell Therapy for RRMM in the Community Oncology Setting"

EP. 23 Bispecific Antibodies Versus CAR T-Cell Therapy for RRMM in the Community Oncology Setting

$Video 9 - "Unmet Needs in Relapsed or Refractory Multiple Myeloma"$

EP. 24 Unmet Needs in Relapsed or Refractory Multiple Myeloma

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Related to this article

Histology image of flame shaped plasma cells promoting multiple myeloma condition understanding | Image Credit: © AbstractAI - stock.adobe.com

November 12th, 2026

Belantamab Mafodotin Moves Into Lenalidomide-Refractory Myeloma in Updated NCCN Guidelines

Category 1 placement for belantamab mafodotin plus bortezomib and dexamethasone puts guideline support ahead of the FDA label.

Trending on Pharmacy Times

FDA Reportedly Shelves Commissioner's National Priority Voucher Program

Glucose Monitoring: Timing Makes Every Reading Count

Belantamab Mafodotin Moves Into Lenalidomide-Refractory Myeloma in Updated NCCN Guidelines

Formulary Fit: Preparing Pathways and Protocols for a New Class of Antithrombotic Therapy

Inside the OCEANIC-STROKE Trial and What Asundexian Means for the Future of Stroke Prevention